ROQ vs. IXI, HEMO, OBD, BVX, CIZ, FAB, APTA, GENF, ONC, and EVG
Should you be buying Roquefort Therapeutics stock or one of its competitors? The main competitors of Roquefort Therapeutics include IXICO (IXI), Hemogenyx Pharmaceuticals (HEMO), Oxford BioDynamics (OBD), BiVictriX Therapeutics (BVX), Cizzle Biotechnology (CIZ), Fusion Antibodies (FAB), Aptamer Group (APTA), Genflow Biosciences (GENF), Oncimmune (ONC), and Evgen Pharma (EVG). These companies are all part of the "biotechnology" industry.
Roquefort Therapeutics vs.
Roquefort Therapeutics (LON:ROQ) and IXICO (LON:IXI) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, community ranking, institutional ownership, dividends, analyst recommendations, risk and earnings.
Roquefort Therapeutics has higher earnings, but lower revenue than IXICO. IXICO is trading at a lower price-to-earnings ratio than Roquefort Therapeutics, indicating that it is currently the more affordable of the two stocks.
1.7% of Roquefort Therapeutics shares are owned by institutional investors. Comparatively, 56.0% of IXICO shares are owned by institutional investors. 60.4% of Roquefort Therapeutics shares are owned by company insiders. Comparatively, 30.3% of IXICO shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, Roquefort Therapeutics' average media sentiment score of 0.00 equaled IXICO'saverage media sentiment score.
Roquefort Therapeutics has a beta of 0.05, meaning that its share price is 95% less volatile than the S&P 500. Comparatively, IXICO has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500.
IXICO has a net margin of -31.10% compared to Roquefort Therapeutics' net margin of -57,057.07%. IXICO's return on equity of -19.14% beat Roquefort Therapeutics' return on equity.
IXICO received 144 more outperform votes than Roquefort Therapeutics when rated by MarketBeat users.
Summary
IXICO beats Roquefort Therapeutics on 7 of the 12 factors compared between the two stocks.
Get Roquefort Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ROQ and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Roquefort Therapeutics Competitors List
Related Companies and Tools
This page (LON:ROQ) was last updated on 2/22/2025 by MarketBeat.com Staff
